Oral SERD Spotlight. Plus: Setbacks at FDA— a BioCentury podcast

The expansion of the oral selective estrogen receptor degrader landscape

As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury’s Lauren Martz assesses how the oral SERD landscape is evolving.

Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy from Disc Medicine Inc. (NASDAQ:IRON) and a vaccine from Moderna Inc. (NASDAQ:MRNA) and why he is calling on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA’s CSO, CMO and director of CBER.

Dig deeper into this week’s episode:

• Oral SERD field expands — bar for differentiation rises
• Pharma CEOs should demand Prasad’s departure
• MAHA movement outlines anti-vaccine strategy
• Disc setback deepens questions about FDA’s accelerated approval commitment, value of new vouchers